FarmaKology Newsletter - Issue #25
Biohope is a commercial stage biomedical company focused in the R&D, IP protection and regulatory clearance of PRECISION MEDICINE IVD tools, for chronic inflammatory conditions. Biohope has developed an IVD kit called Immunobiogram® to personalize drug treatment for patients with a renal transplant and rheumatoid arthritis. Immunobiogram® has shown positive results in our Clinical Trials and it is ready to go to market in 2020 through partners and licensees around the world.
SoftServe's XR Molecular Combines Mixed Reality and AI for Faster Drug Discovery
SoftServe, a leading digital authority and consulting company, announces XR Molecular, the company's platform that unites extended realityand artificial intelligence to enable early-stage drug discovery researchers to generate new compounds, visualize them, and examine the molecular structure. By using this powerful combination of XR and AI, developers can generate new drugs faster and interactively explore the structure and key properties of molecules, all in one solution.
Antibiotics not necessary for most toothaches, according to ADA
The American Dental Association (ADA) recently announced a new guideline indicating that in most cases, antibiotics are not recommended for toothaches. This guidance, published in the November 2019 issue of the Journal of the American Dental Association, aligns with the ADA’s longstanding antibiotic stewardship efforts and its pledged commitment to the U.S. government’s Antimicrobial Resistance Challenge.
Piramal, BerGenBio Partner on Leukemia Drug
Piramal Pharma Solutions has partnered with BerGenBio ASA on the development of bemcentinib for the treatment of elderly patients with relapsed Acute Myeloid Leukemia. Bemcentinib was recently granted Fast Track designation by the U.S. FDA, as there are currently no marketed drugs specifically approved for relapsed AML patients, representing a significant unmet medical need.
Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone
Mission Therapeutics , a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes , and AbbVie , a global, research-driven bio pharmaceutical company, today announced the identification of several DUBs as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration.
Research & Study
Medicine against bone disease found in the leaves of saussurea
Researchers Find Clue to Prevent Addiction Relapse
Minerals Can Fight Antibiotic-Resistant Bacteria
Listen to Ep. 71 - Does Vitamin D Work Better Than The Flu Shot? and seventy-seven more episodes by The Vaccine Conversation With Melissa And Dr. Bob, free! No signup or install needed. Ep. 78 - Special Announcement: Our Mission For The Coming Year. Ep. 77 - Overview of Vaccine-Targeted Illnesses: Part 2.